William Rieflin
Chairman at NGM BIOPHARMACEUTICALS, INC.
Net worth: 850 604 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Klausner | M | 72 | 6 years | |
| David Goeddel | M | 72 | 16 years | |
| Catherine Friedman | F | 63 | 16 years | |
| Lynn Seely | M | 65 | 3 years | |
| Valerie Pierce | F | 61 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 10 years |
| Nancy Thornberry | F | 67 |
Kallyope, Inc.
 Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | 9 years |
| David Woodhouse | M | 54 | 9 years | |
| Brian Wong | M | 52 | 9 years | |
| Douglas Giordano | M | 61 | 8 years | |
| Margaret M. Madden | F | - | 8 years | |
| Roger Perlmutter | M | 71 | 3 years | |
| Mary Gray | M | 71 | 5 years | |
| Michael Giordano | M | 66 | 6 years | |
| Ellen Rose | F | - | 3 years | |
| Elizabeth Nabel | M | 72 | 3 years | |
| Jay Galeota | M | 57 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | 3 years |
| Linda Kozick | F | 66 | 8 years | |
| Lori Lyons-Williams | F | 46 | 3 years | |
| Matthew Lang | M | 48 | 1 years | |
| Stephen Hill | M | 53 | 5 years | |
| Daniel Kaplan | M | - | 16 years | |
| Hans Bishop | M | 59 | 6 years | |
| David J. Wustrow | M | 65 | 13 years | |
| Wendye Robbins | M | 63 | 5 years | |
| Laurent Fischer | M | 60 |
Lycia Therapeutics, Inc.
 Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | - |
| Rodney Young | M | 61 | 5 years | |
| Robert Nelsen | M | 60 | 6 years | |
| Tom Maniatis | M | 80 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | 10 years |
| Otis Brawley | M | 64 | 3 years | |
| Michael J. Bakes | M | - |
Cumbre Pharmaceuticals, Inc.
 Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | - |
| Nipun Davar | M | - | - | |
| Aetna Wun Trombley | M | 45 |
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | 4 years |
| Timothy Kutzkey | M | 49 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | - |
| Adnan Rahman | M | - | 2 years | |
| Jim Farmer | M | - | 2 years | |
| Joyce Q. Acbay | F | - | 4 years | |
| Irene Perlich | F | - | 3 years | |
| Amy Schulman | F | 63 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | - |
| Charles Newton | M | 53 | 3 years | |
| Jennifer Nicholson | F | - | 2 years | |
| Paul Kassner | M | 58 | 8 years | |
| Jeffrey Friedman | M | - |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | - |
| Gary Lee | M | 47 | 2 years | |
| Aljanae Reynolds | M | - | - | |
| Anderson Timothy | M | - |
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | - |
| Richard D. Goold | M | 64 | 5 years | |
| Bryan Supran | M | - | 8 years | |
| Simon Lynch | M | - |
Cumbre Pharmaceuticals, Inc.
Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | - |
| Hsiao Lieu | M | 53 | 5 years | |
| Dirk Brockstedt | M | 55 | 6 years | |
| Michael L. Kranda | M | 69 |
Cumbre Pharmaceuticals, Inc.
Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | - |
| Peter Hecht | M | 60 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | 4 years |
| Sylvia R. Wheeler | F | 63 | - | |
| Josh Wolfe | M | 46 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | - |
| Gwen R. Carscadden | F | 62 | 2 years | |
| J. Goater | M | 48 |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | 2 years |
| William Ho | M | 58 | 9 years | |
| Michael Listgarten | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Berns | M | 57 | 11 years | |
| Mark Leschly | M | 55 | 20 years | |
| David Perry | M | 56 | 12 years | |
| Jin Long Chen | M | 61 | 16 years | |
| Vincent Angotti | M | 56 | 8 years | |
| Peter Svennilson | M | 62 | 13 years | |
| Ronald W. Barrett | M | 68 | 16 years | |
| Lucy Shapiro | M | 83 | 16 years | |
| John Freund | M | 70 | 17 years | |
| Gianna M. Bosko | F | 54 | 10 years | |
| Hui Tian | M | - |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 20 years |
| Steven McKnight | M | 75 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 13 years |
| Siobhan Mangini | F | 43 | 3 years | |
| Aetna Wun Trombley | M | 45 | 9 years | |
| Elizabeth Homans | F | 58 | - | |
| Graeme Bell | M | 57 | 1 years | |
| Shelly Guyer | F | 63 | 5 years | |
| Gregory T. Bates | M | 65 | - | |
| Eric J. Hall | M | 69 | - | |
| Carole Ho | M | 51 | 4 years | |
| Steve Young | M | 55 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 4 years |
| Zhi Hong | M | 60 | 2 years | |
| Qing Hai Zhao | M | 64 | 2 years | |
| McHenry Tichenor | M | 68 | 11 years | |
| Andrew Perlman | M | 76 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 11 years |
| David Savello | M | 78 | - | |
| Wendell Wierenga | M | 76 | 2 years | |
| Heather Turner | F | 51 | 4 years | |
| Per G. H. Lofberg | M | 76 | 2 years | |
| Ernest Mario | M | 85 | 3 years | |
| Kenneth J. Nussbacher | M | 70 | 10 years | |
| James M. Gower | M | 75 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 4 years |
| Anders Hove | M | 58 | 11 years | |
| Dennis Fenton | M | 72 | 7 years | |
| Ryan Sullivan | M | 48 | 2 years | |
| Robert W. Overell | M | 69 | 6 years | |
| Helen Kim | F | 61 | 5 years | |
| David Schnell | M | 64 | 13 years | |
| Richard Markham | M | 73 | 7 years | |
| Suzanne Hooper | F | 58 | 6 years | |
| Keith Leonard | M | 62 | 2 years | |
| Carla Daniel | F | - |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William Rieflin
- Personal Network